AlphaMark Advisors’s Emergent Biosolutions EBS Stock Holding History

AlphaMark Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,979	Closed	-$723K	–	482
2018 Q3	$723K	Sell	10,979 -548	-5%	-$32K	0.29%	73
2018 Q2	$582K	Hold	11,527	–	–	0.24%	78
2018 Q1	$607K	Hold	11,527	–	–	0.26%	75
2017 Q4	$536K	Buy	+11,527	New	+$485K	0.21%	78

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AlphaMark Advisors's EBS Position: Q4 2018 in Review

AlphaMark Advisors sold out of Emergent Biosolutions (EBS) in Q4 2018, closing a stake of 10,979 shares — an estimated $723K sold.

AlphaMark Advisors first reported a position in EBS in Q4 2017 and held it in 4 quarters. The position peaked at $723K in Q3 2018. 297 funds tracked by Wall St. Rank hold EBS as of Q4 2018.

AlphaMark Advisors reported no remaining Emergent Biosolutions position as of Q4 2018 after selling out during the quarter.
AlphaMark Advisors sold 10,979 Emergent Biosolutions shares in Q4 2018, an estimated $723K.
AlphaMark Advisors first reported a position in Emergent Biosolutions in Q4 2017 and held it in 4 quarters.
AlphaMark Advisors's Emergent Biosolutions position peaked at $723K in Q3 2018.
297 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2018.

Based on AlphaMark Advisors's 13F filing for Q4 2018, filed 6 Feb 2019.